Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of INCB050465 in relapsed or refractory diffuse large B-cell lymphoma
2016-002205-19Phase 2Unknown
- Sponsor
- Incyte
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of parsaclisib in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Incyte. Primary endpoint: Objective response rate in Group A. Status: unknown.
02
Drugs
parsaclisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2016-002205-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002205-19.